Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

o TAXUS (7.4 percent for XIENCE V vs. 11.4 percent for TAXUS, p-value=0.0038).

In addition, XIENCE V demonstrated a 77 percent lower rate of stent thrombosis, defined as definite or probable according to ARC (0.9 percent for XIENCE V vs. 3.9 percent for TAXUS, p-value=<0.0001); a 60 percent lower rate of TVR (3.1 percent for XIENCE V vs. 7.7 percent for TAXUS, p-value=<0.0001); a 56 percent lower rate of TLR (2.6 percent XIENCE V vs. 5.9 percent TAXUS, p-value=0.0005); and a 49 percent lower rate of non-fatal MI (3.9 percent XIENCE V for vs. 7.6 percent for TAXUS, p-value=0.0009).

The stent thrombosis rate for XIENCE V between one and two years increased from 0.7 percent at one year to 0.9 percent at two years, while the TAXUS arm increased from 2.6 percent at one year to 3.9 percent at two years. At two years, 88.6 percent of XIENCE V patients and 84.8 percent of TAXUS patients had discontinued dual-antiplatelet therapy.

"The COMPARE results show that the gap in stent thrombosis rates between XIENCE V and TAXUS Liberte widened from 1.9 percent at one year to 3.0 percent at two years," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "The COMPARE investigators have provided some of the first major insights into the comparative long-term differences in stent thrombosis rates between one and two years for different stent platforms."

"The two-year results presented today for the COMPARE trial and for the SPIRIT IV trial demonstrate impressive outcomes for XIENCE V compared to TAXUS Liberte and TAXUS Express, respectively," said Robert Hance, senior vice president, vascular, Abbott. "Both of these trials show the differences in the performance of these drug eluting stents and add to the ever-growing body of safety and efficacy data for XIENCE V – reinforcing why XIENCE V continues to be the market-leading drug eluting stent."

About The
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Patient engagement has become ... organizations are turning to an assortment of marketing ... part of this evolving approach to patient engagement, ... and engage patients throughout their experiences with a ... By mapping the patient journey and employing a ...
(Date:7/11/2014)... Fla. , July 11, 2014  Rock Creek ... biotechnology company, today announced that the Food and Drug ... will provide comments on RCP,s Investigational New Drug ("IND") ... clinical trial in the US. Dr. ... agency,s review and comments on our IND. When we ...
(Date:7/11/2014)... , July 11, 2014 ... "Scintillator Market by Composition of Material, Application (Healthcare, ... others), End Product (Personal Instrument, Hand-Held Instruments, Fixed, ... and Analysis to 2013 - 2020", published by MarketsandMarkets, the ... CAGR of 5.62% from 2014 to 2020, and ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... As reported in this July 1st article ... the June 25th, 2014 Supreme Court ruling in Riley v ... It was also met with both cheers and jeers when ... seen from an individual privacy perspective, or a law enforcement ... now precedent which will require law enforcement officials to obtain ...
(Date:7/12/2014)... United Arab Emirates (PRWEB) July 12, 2014 ... another Los Angeles basketball legend is heading to the ... scorer and six-time champion will be in the UAE ... & Fitness Weekend in support of diabetes awareness. The ... an award-winning entertainment marketing and event management company based ...
(Date:7/12/2014)... 12, 2014 Praeclarus Press ... as a valuable new resource for women in need ... American women work away from their children. Today’s mothers ... benefits of breastfeeding, but often feel unsupported when it ... babies. With its evidence-based insights, and written by Nancy ...
(Date:7/12/2014)... Restore My Vision Today is a ... a couple boasting very impressive credentials on the field ... Today as a way to help consumers do without ... their respective patients’ treatments . , In ... trove of pertinent information relevant to eye care like:, ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... first and only FDA-approved once-daily amoxicillin will be ... 7 MiddleBrook Pharmaceuticals, Inc. (Nasdaq: ... of Moxatag (amoxicillin extended-release) Tablets, 775mg, will begin ... hired over half of its 270-person field force ...
... Jan. 7 RRY Publications announced that the ... of stem cell company executives, scientists and investors, ... The Summit is an intensive one-day event where ... embryonic stem cells, the successful path to stem ...
... Neurosciences, Inc. ( OTC Bulletin Board: ILNS ), ... therapeutic agents for the treatment and prevention of ... granted a non-exclusive License to a top-tier global ... patent applications related to antibodies and methods of ...
... DTC Perspectives Inc., the leading DTC training, publishing and ... and DTC Perspectives Magazine , announced today the ... will serve the unmet needs of OTC Marketers, and ... to focus on the myriad of emerging issues OTC ...
... pleased to announce the selection of Clifford Brownstein as their new ... ... 2009 -- The National Association of Therapeutic Schools and Programs ... as their new Executive Director. , , , , ,Clifford ...
... Neurological Surgery, P.C., the largest private Neurosurgery practice on Long Island and ... treatment of children and adults afflicted with complex disorders of the brain ... States Army Reserve. , ... Great Neck, NY (PRWEB) January 7, 2009 ...
Cached Medicine News:Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 3Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 4Health News:Stem Cell Product Commercialization Focus of Summit 2Health News:Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications 2Health News:Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications 3Health News:Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications 4Health News:Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications 5Health News:Crucial OTC Marketing Issues to be Addressed by New OTC Perspectives Division of DTC Perspectives, Inc. 2Health News:National Association of Therapeutic Schools and Programs Announces New Executive Director 2Health News:Neurological Surgery, P.C. of Long Island, NY Announces the Addition of Pediatric Neurosurgeon, Elizabeth M. Trinidad, M.D. 2Health News:Neurological Surgery, P.C. of Long Island, NY Announces the Addition of Pediatric Neurosurgeon, Elizabeth M. Trinidad, M.D. 3Health News:Neurological Surgery, P.C. of Long Island, NY Announces the Addition of Pediatric Neurosurgeon, Elizabeth M. Trinidad, M.D. 4
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
With a large white surface and a black X in the center, knockout really makes you look the heavyweight....
Icefire has ice crystals on the top of a cool blue iris....
This design features a solid red iris....
Medicine Products: